Zacks Research Weighs in on Alkermes plc’s Q4 2025 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research increased their Q4 2025 EPS estimates for Alkermes in a research report issued on Tuesday, June 25th. Zacks Research analyst R. Department now forecasts that the company will earn $0.57 per share for the quarter, up from their previous forecast of $0.56. The consensus estimate for Alkermes’ current full-year earnings is $2.27 per share.

A number of other analysts also recently weighed in on ALKS. StockNews.com downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Robert W. Baird started coverage on shares of Alkermes in a research report on Tuesday, March 19th. They issued an “outperform” rating and a $37.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 target price on shares of Alkermes in a research note on Monday, April 1st. HC Wainwright reissued a “neutral” rating and set a $35.00 price objective on shares of Alkermes in a research note on Tuesday, June 4th. Finally, Jefferies Financial Group lifted their price target on shares of Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Alkermes currently has an average rating of “Moderate Buy” and a consensus price target of $36.50.

Alkermes Stock Performance

Shares of ALKS opened at $24.29 on Thursday. The company’s fifty day moving average is $24.27 and its 200-day moving average is $26.59. Alkermes has a 12 month low of $22.01 and a 12 month high of $33.20. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of 9.60, a price-to-earnings-growth ratio of 0.49 and a beta of 0.47. The company has a quick ratio of 2.77, a current ratio of 3.20 and a debt-to-equity ratio of 0.23.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.15). The firm had revenue of $350.37 million for the quarter, compared to analyst estimates of $360.26 million. Alkermes had a net margin of 25.17% and a return on equity of 20.31%. The firm’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.10) EPS.

Hedge Funds Weigh In On Alkermes

Several large investors have recently bought and sold shares of the stock. Alps Advisors Inc. raised its stake in Alkermes by 0.4% in the 3rd quarter. Alps Advisors Inc. now owns 122,916 shares of the company’s stock valued at $3,443,000 after acquiring an additional 529 shares during the period. Fisher Asset Management LLC boosted its stake in Alkermes by 1.0% in the fourth quarter. Fisher Asset Management LLC now owns 59,942 shares of the company’s stock worth $1,663,000 after buying an additional 572 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Alkermes by 0.9% in the fourth quarter. Victory Capital Management Inc. now owns 76,718 shares of the company’s stock worth $2,128,000 after buying an additional 675 shares in the last quarter. CWM LLC boosted its stake in shares of Alkermes by 36.7% during the first quarter. CWM LLC now owns 2,732 shares of the company’s stock valued at $74,000 after purchasing an additional 733 shares during the period. Finally, McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Alkermes during the fourth quarter valued at approximately $30,000. 95.21% of the stock is currently owned by institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.